Manidipino Teva

Manidipine, the active ingredient in Manidipino Teva, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for oral use. It treats hypertension by lowering elevated blood pressure in adult patients. GNH USA supplies Manidipino Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is indicated for conditions affecting the cardiovascular system where blood pressure control is required. - Hypertension: reduces systolic and diastolic blood pressure in essential hypertension. - Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults. - Primary hypertension: provides long‑term blood pressure management in patients with newly diagnosed high blood pressure.

Manidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness of the skin, especially on the face. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, particularly after standing. - Tachycardia: increased heart rate without other cardiac pathology. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: abnormal heart rhythms, including ventricular tachycardia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway requiring urgent care.

Manidipine should be used with careful clinical monitoring to ensure safety and efficacy. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: adjust use in patients with liver disease. - Elderly patients: start at lower doses and monitor for dizziness. - Concomitant antihypertensives: watch for additive blood‑pressure‑lowering effects. - Discontinuation: do not stop abruptly; taper under medical guidance. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its antihypertensive effect or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive heart‑rate reduction, monitor pulse. - Diuretics: may enhance antihypertensive effect, watch electrolytes. - NSAIDs: can blunt antihypertensive response, monitor renal function.